JWCTF (JW (Cayman) Therapeutics Co) Moat Score: 4/10 (As of Jul. 02, 2026)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
28 GF Score
Price $0.23
GF Value $0.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Moat Score?

JW (Cayman) Therapeutics Co JWCTF -1.85% 28 Moat Score is 4 as of Jul. 02, 2026. GuruFocus rates JWCTF with a GF Score™ of 28/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, JW (Cayman) Therapeutics Co ranks better than 88.79% on this metric.

JW (Cayman) Therapeutics Co has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

JW (Cayman) Therapeutics Co has Narrow Moat: JW (Cayman) Therapeutics Co Ltd has a discernible but modest moat with some valuable intellectual property in the biotech sector. However, it faces high competition and regulatory challenges.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes JW (Cayman) Therapeutics Co might have Narrow Moat - Discernible but modest moat.

JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

JW (Cayman) Therapeutics Co Moat Score Related Terms

JWCTF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Moat Score distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Moat Score falls into.


JWCTF
28GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Moat Score of 4 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is JW (Cayman) Therapeutics Co's Moat Score too high?
JW (Cayman) Therapeutics Co's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. JW (Cayman) Therapeutics Co's value of 4 is 100% above this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #157 out of 1400 companies for Moat Score. This places JW (Cayman) Therapeutics Co in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. JW (Cayman) Therapeutics Co's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.23 — trading 59.1% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Moat Score is 4 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.23 is trading 59.1% below its estimated GF Value™ of $0.57. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Moat Score: 4
  • GF Value™: $0.57 vs. price of $0.23 (59.1% below fair value)
  • GF Score™: 28/100 with 3 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1400)

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score

Get the complete analysis for JWCTF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.57
GF Value